Company intelligence / Profile preview

Sinoveda

Edmonton, Alberta, Canadasinoveda.com ↗

Ownership: Private
Development stage: Commercial

Overview

Sinoveda leverages its patented Pharmaceutical Platform Technology® to identify and standardize effective plant-based combination therapies. Its lead program for Long Covid demonstrated encouraging results in a small observational study and was approved as AntiCo in Hong Kong. The company’s pipeline includes both marketed products and preclinical candidates targeting oncology and metabolic diseases.

Therapeutic areas: OncologyCardiovascularInfectious Diseases
Modalities: Small molecules (plant-derived compounds)Combination therapies (botanical pharmaceuticals)
Industry: Biotech

Drug pipeline

1 asset

Proflexa

Unknown

Beyond the preview

Go deeper on Sinoveda.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinoveda.

Explore the full profile